{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:15Z","timestamp":1776413115056,"version":"3.51.2"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.2169\/internalmedicine.6198-25","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T22:07:26Z","timestamp":1756332446000},"page":"997-1000","source":"Crossref","is-referenced-by-count":0,"title":["Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab"],"prefix":"10.2169","volume":"65","author":[{"given":"Hayato","family":"Tada","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kanazawa University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Okamura T, Tsukamoto K, Arai H, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb 31: 641-853, 2024.","DOI":"10.5551\/jat.GL2022"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Doi T, Langsted A, Nordestgaard BG. Lipoproteins, cholesterol, and atherosclerotic cardiovascular diseases in East Asians and Europeans. J Atheroscler Thromb 30: 1525-1546, 2023.","DOI":"10.5551\/jat.RV22013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mitani H, Suzuki K, Ako J, et al. Achievement rates for low-density lipoprotein cholesterol goals in patients at high risk of atherosclerotic cardiovascular disease in a real-world setting in Japan. J Atheroscler Thromb 30: 1622-1634, 2023.","DOI":"10.5551\/jat.63940"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tada H, Usui S, Sakata K, Takamura M, Kawashiri MA. Low-density lipoprotein cholesterol levels cannot be too low: considerations from clinical trials, human genetics, and biology. J Atheroscler Thromb 27: 489-498, 2020.","DOI":"10.5551\/jat.RV17040"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Harada-Shiba M, Ohtake A, Sugiyama D, et al. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. J Atheroscler Thromb 30: 531-557, 2023.","DOI":"10.5551\/jat.CR006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Harada-Shiba M, Arai H, Ohmura H, et al. Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. J Atheroscler Thromb 30: 558-586, 2023.","DOI":"10.5551\/jat.CR005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tada H, Nohara A, Usui S, et al. Coronary artery and carotid artery plaques in patients with heterozygous familial hypercholesterolemia. JACC Adv 2: 100594, 2023.","DOI":"10.1016\/j.jacadv.2023.100594"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ogura M, Okazaki S, Okazaki H, et al. Transitional medicine of intractable primary dyslipidemias in Japan. J Atheroscler Thromb 31: 501-519, 2024.","DOI":"10.5551\/jat.RV22016"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Takeji Y, Tada H, Ogura M, et al.; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labor, and Welfare of Japan. Clinical characteristics of homozygous familial hypercholesterolemia in Japan: a survey using a national database. JACC Asia 3: 881-891, 2023.","DOI":"10.1016\/j.jacasi.2023.07.011"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Rodbard HW, Rosenstock J, Canani LH, et al.; PIONEER 2 Investigators. Oral semaglutide versus empagliflozin in patients with uncontrolled type 2 diabetes on metformin: the PIONEER 2 trial. Diabetes Care 42: 2272-2281, 2019.","DOI":"10.2337\/dc19-0883"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rakipovski G, Rolin B, N\u00f8hr J, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE<sup>-\/-<\/sup> and LDLr<sup>-\/-<\/sup> mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci 3: 844-857, 2018.","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun 425: 304-308, 2012.","DOI":"10.1016\/j.bbrc.2012.07.086"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_6198-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:55:24Z","timestamp":1775274924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/7\/65_6198-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6198-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"6198-25"}}